Report from the Advisory Committee on Immunization Practices (ACIP) : Decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4)
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Report from the Advisory Committee on Immunization Practices (ACIP) : Decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4)
Filetype[HTM]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Alternative Title:
    MMWR. Morbidity and mortality weekly report
  • Description:
    At its February 2008 meeting, the Advisory Committee on Immunization Practices (ACIP) decided not to recommend routine vaccination of children aged 2--10 years against meningococcal disease unless the child is at increased risk for the disease. This report summarizes the deliberations of ACIP and the rationale for its decision and restates existing recommendations for meningococcal vaccination among children aged 2--10 years at increased risk for meningococcal disease. ACIP continues to recommend routine vaccination against meningococcal disease for all persons aged 11--18 years and those persons aged 2--55 years who are at increased risk for meningococcal disease (1--3).
  • Subject:
  • Pubmed ID:
    18451758
  • Collection(s):
    Advisory Committee on Immunization Practices (ACIP)
    Guidelines and Recommendations
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 515.21 KB]
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    August 10, 2007
    Source:
    MMWR. Morbidity and mortality weekly report. 2007; 56(31):794-5.
    Description:
    In January 2005, a quadrivalent meningococcal polysaccharide- protein conjugate vaccine (MCV4) (Menactra™, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11–55 years. In May 2005, the Advisory Committee on...
    Status:
    superseded
    File Type:
    Filetype[PDF - 515.21 KB]
  2. Filetype[PDF - 319.43 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). United States. Advisory Committee on Immunization Practices..
    Published Date:
    April 4, 2008
    Source:
    MMWR. Morbidity and mortality weekly report. 2008; 57(13):343-4.
    Description:
    This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration. In February 2000, PCV7, marketed as Prevnar and ...
    Status:
    superseded
    File Type:
    Filetype[PDF - 319.43 KB]
  3. Filetype[HTM]
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    January 28, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(3):72-6.
    Description:
    On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines (Menveo, Novartis; and Menactra, Sanofi Pasteur...
    Status:
    superseded
    File Type:
    Filetype[HTM]
  4. Filetype[PDF - 604.42 KB]
    Personal Author:
    Novak, Ryan T; Kambou, Jean Ludovic; Diomandé, Fabien V K; Tarbangdo, Tiga F; Ouédraogo-Traoré, Rasmata; Sangaré, Lassana; Lingani, Clement; Martin, Stacey W; Hatcher, Cynthia; Mayer, Leonard W; LaForce, F Marc; Avokey, Fenella; Djingarey, Mamoudou H; Messonnier, Nancy E; Tiendrébéogo, Sylvestre R; Clark, Thomas A;
    Published Date:
    Jul 18 2012
    Source:
    Lancet Infect Dis. 12(10):757-764.
    Description:
    BackgroundAn affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA–TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national preve...
    File Type:
    Filetype[PDF - 604.42 KB]
  5. Filetype[PDF - 317.21 KB]
    Personal Author:
    Levine, Orin S.; Schwartz, Benjamin; Van Beneden, Chris A.; Whitney, Cynthia G.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.). National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases.. National Immunization Program (Centers for Disease Control and Prevention). Division of Epidemiology and Surveillance..
    Published Date:
    October 6, 2000
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 49, no. RR-9 PMID:11055835:MODS 11055835
    Description:
    In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar, marketed by Wyeth Lederle Vaccines) was licensed for use among infants and young children. CDC's Advisory Committee on Immunization Practices (ACIP) recommen...
    File Type:
    Filetype[PDF - 317.21 KB]